1665 Ellis Street
Kelowna, BC V1Y 2B3
Full Time Employees:
|Mr. Gregory M. McKee M.B.A., M.A., MBA||Exec. Chairman & CEO||N/A||N/A||1964|
|Dr. James P. Gilligan||Pres & Chief Scientific Officer||N/A||N/A||1952|
|Mr. Luke Hayes||Chief Financial Officer||N/A||N/A||N/A|
|Mr. Thomas D'Orazio B.Sc., M.B.A.||Chief Operating Officer||N/A||N/A||N/A|
|Ms. Joy Willis||Director of Investor Relations||N/A||N/A||N/A|
Tryp Therapeutics Inc., a clinical stage pharmaceutical company, focuses on developing compounds with known activity and/or safety profiles for the treatment of rare or orphan diseases and other diseases. The company's lead development program is psilocybin-for-neuropsychiatry (PFN), which is designed to treat neuropsychiatric disorders through the dosing of formulations of synthetic psilocybin. Its PFN program candidates include TRP-8802 for fibromyalgia, hyperphagia in prader-willi syndrome, and other therapies; and TRP-1001, an oral formulation of razoxane evaluating for the treatment of soft tissue sarcoma. Tryp Therapeutics Inc. has an agreement with the University of Michigan to perform research related to its psilocybin-for-neuropsychiatric disorders program; and a service agreement with Fluence to provide design and training for the psychotherapeutic portion of Tryp's clinical trial activities. The company was formerly known as Artos Pharma Corp. and changed its name to Tryp Therapeutics Inc. in June 2020. The company was founded in 2019 and is headquartered in Kelowna, Canada.
Tryp Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.